NY A03973

Allows utilization review agents to require insured patients to try an interchangeable biological product before covering a brand name drug, expanding existing requirements that already apply to AB-rated generic equivalents

Permits insurers to require patients to try a biosimilar before providing coverage for the brand name reference product drug

Authorizes insurers to move a prescription drug to a higher cost-sharing tier (larger deductible, copayment, or coinsurance) when a biosimilar for that drug is added to the formulary, in addition to existing provisions for generics and interchangeable biologics

Applies these changes to insurance law provisions governing both general insurers (section 3242) and corporations (section 4329)

Takes effect immediately upon enactment